Question 1

What is ONP-002?

Accepted Answer

ONP-002 is a Other.

Question 2

How often does ONP-002 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was ONP-002 first tracked by Ergen?

Accepted Answer

First tracked on Apr 13, 2026.

Question 4

When was ONP-002 last mentioned in news?

Accepted Answer

Last active on Apr 20, 2026.

Question 5

What is ONP-002's current news sentiment?

Accepted Answer

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is ONP-002 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving ONP-002?

Accepted Answer

Oragenics Doses First Patient ONP-002 (Apr 13, 2026, 6 articles).

Question 8

How did the "Oragenics Doses First Patient ONP-002" event impact ONP-002?

Accepted Answer

ONP-002 is Oragenics' lead drug candidate for treating concussion and mild traumatic brain injury, currently in Phase IIa clinical trials.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.